188 related articles for article (PubMed ID: 15664488)
1. Clarithromycin co-administered with amikacin attenuates systemic inflammation in experimental sepsis with Escherichia coli.
Giamarellos-Bourboulis EJ; Baziaka F; Antonopoulou A; Koutoukas P; Kousoulas V; Sabracos L; Panagou C; Perrea D; Giamarellou H
Int J Antimicrob Agents; 2005 Feb; 25(2):168-72. PubMed ID: 15664488
[TBL] [Abstract][Full Text] [Related]
2. Clarithromycin: immunomodulatory therapy of experimental sepsis and acute pyelonephritis by Escherichia coli.
Giamarellos-Bourboulis E; Adamis T; Sabracos L; Raftogiannis M; Baziaka F; Tsaganos T; Koutoukas P; Plachouras D; Karayannacos P; Giamarellou H
Scand J Infect Dis; 2005; 37(1):48-54. PubMed ID: 15764190
[TBL] [Abstract][Full Text] [Related]
3. Clarithromycin is an effective immunomodulator in experimental pyelonephritis caused by pan-resistant Klebsiella pneumoniae.
Giamarellos-Bourboulis EJ; Tziortzioti V; Koutoukas P; Baziaka F; Raftogiannis M; Antonopoulou A; Adamis T; Sabracos L; Giamarellou H
J Antimicrob Chemother; 2006 May; 57(5):937-44. PubMed ID: 16549515
[TBL] [Abstract][Full Text] [Related]
4. Clarithromycin is an effective immunomodulator when administered late in experimental pyelonephritis by multidrug-resistant Pseudomonas aeruginosa.
Giamarellos-Bourboulis EJ; Antonopoulou A; Raftogiannis M; Koutoukas P; Tsaganos T; Tziortzioti V; Panagou C; Adamis T; Giamarellou H
BMC Infect Dis; 2006 Feb; 6():31. PubMed ID: 16504031
[TBL] [Abstract][Full Text] [Related]
5. Immunomodulatory clarithromycin treatment of experimental sepsis and acute pyelonephritis caused by multidrug-resistant Pseudomonas aeruginosa.
Giamarellos-Bourboulis EJ; Adamis T; Laoutaris G; Sabracos L; Koussoulas V; Mouktaroudi M; Perrea D; Karayannacos PE; Giamarellou H
Antimicrob Agents Chemother; 2004 Jan; 48(1):93-9. PubMed ID: 14693524
[TBL] [Abstract][Full Text] [Related]
6. Oleuropein: a novel immunomodulator conferring prolonged survival in experimental sepsis by Pseudomonas aeruginosa.
Giamarellos-Bourboulis EJ; Geladopoulos T; Chrisofos M; Koutoukas P; Vassiliadis J; Alexandrou I; Tsaganos T; Sabracos L; Karagianni V; Pelekanou E; Tzepi I; Kranidioti H; Koussoulas V; Giamarellou H
Shock; 2006 Oct; 26(4):410-6. PubMed ID: 16980890
[TBL] [Abstract][Full Text] [Related]
7. n-6 polyunsaturated fatty acids enhance the activities of ceftazidime and amikacin in experimental sepsis caused by multidrug-resistant Pseudomonas aeruginosa.
Giamarellos-Bourboulis EJ; Mouktaroudi M; Adamis T; Koussoulas V; Baziaka F; Perrea D; Karayannacos PE; Giamarellou H
Antimicrob Agents Chemother; 2004 Dec; 48(12):4713-7. PubMed ID: 15561848
[TBL] [Abstract][Full Text] [Related]
8. Immunomodulatory intervention in sepsis by multidrug-resistant Pseudomonas aeruginosa with thalidomide: an experimental study.
Giamarellos-Bourboulis EJ; Bolanos N; Laoutaris G; Papadakis V; Koussoulas V; Perrea D; Karayannacos PE; Giamarellou H
BMC Infect Dis; 2005 Jun; 5():51. PubMed ID: 15978135
[TBL] [Abstract][Full Text] [Related]
9. Experimental sepsis using Pseudomonas aeruginosa: the significance of multi-drug resistance.
Giamarellos-Bourboulis EJ; Koussoulas V; Panagou C; Adamis T; Baziaka F; Skiadas I; Perrea D; Dionyssiou-Asteriou A; Giamarellou H
Int J Antimicrob Agents; 2004 Oct; 24(4):357-61. PubMed ID: 15380261
[TBL] [Abstract][Full Text] [Related]
10. Immunomodulatory effect of three-day continuous administration of clarithromycin for experimental sepsis due to multidrug-resistant Pseudomonas aeruginosa.
Baziaka F; Giamarellos-Bourboulis EJ; Raftogiannis M; Adamis T; Tziortzioti V; Sabracos L; Chrisofos M; Koutoukas P; Giamarellou H; Douzinas EE
J Chemother; 2008 Feb; 20(1):63-8. PubMed ID: 18343746
[TBL] [Abstract][Full Text] [Related]
11. The impact of multidrug resistance on the pathogenicity of Escherichia coli: an experimental study.
Bristianou M; Panagou C; Adamis T; Raftogiannis M; Antonopoulou A; Chrisofos M; Galani I; Kanellakopoulou K; Tsaganos T; Giamarellos-Bourboulis EJ
Int J Antimicrob Agents; 2008 Mar; 31(3):216-23. PubMed ID: 18248963
[TBL] [Abstract][Full Text] [Related]
12. Antimicrobial-induced endotoxaemia in patients with sepsis in the field of acute pyelonephritis.
Giamarellos-Bourboulis EJ; Perdios J; Gargalianos P; Kosmidis J; Giamarellou H
J Postgrad Med; 2003; 49(2):118-22. PubMed ID: 12867685
[TBL] [Abstract][Full Text] [Related]
13. Clarithromycin modulates immune responses in experimental peritonitis.
Atmatzidis S; Koutelidakis I; Chatzimavroudis G; Louis K; Pistiki A; Roditis K; Atmatzidis K; Giamarellos-Bourboulis EJ
Int J Antimicrob Agents; 2011 Apr; 37(4):347-51. PubMed ID: 21353492
[TBL] [Abstract][Full Text] [Related]
14. Continuous administration of PBP-2- and PBP-3-specific beta-lactams causes higher cytokine responses in murine Pseudomonas aeruginosa and Escherichia coli sepsis.
Buijs J; Dofferhoff AS; Mouton JW; van der Meer JW
J Antimicrob Chemother; 2007 May; 59(5):926-33. PubMed ID: 17395686
[TBL] [Abstract][Full Text] [Related]
15. The significance of oxidant/antioxidant balance for the pathogenesis of experimental sepsis by multidrug-resistant Pseudomonas aeruginosa.
Koussoulas V; Giamarellos-Bourboulis EJ; Adamis T; Mouktaroudi M; Sabracos L; Perrea D; Giamarellou H; Dionyssiou-Asteriou A
Prostaglandins Leukot Essent Fatty Acids; 2005 Jan; 72(1):41-7. PubMed ID: 15589398
[TBL] [Abstract][Full Text] [Related]
16. Reverse kinetics of angiopoietin-2 and endotoxins in acute pyelonephritis: Implications for anti-inflammatory treatment?
Safioleas K; Giamarellos-Bourboulis EJ; Carrer DP; Pistiki A; Sabracos L; Deliveliotis C; Chrisofos M
Cytokine; 2016 May; 81():28-34. PubMed ID: 26844659
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of the combination of tachyplesin III and clarithromycin in rat models of Escherichia coli sepsis.
Cirioni O; Ghiselli R; Silvestri C; Kamysz W; Orlando F; Riva A; Kamysz E; Castelletti S; Rocchi M; Saba V; Scalise G; Giacometti A
Antimicrob Agents Chemother; 2008 Dec; 52(12):4351-5. PubMed ID: 18779356
[TBL] [Abstract][Full Text] [Related]
18. The anti-inflammatory activity of clarithromycin inhibits TNFalpha production and prolongs survival following lipopolysaccharide administration in mice.
Tkalcević VI; Bosnjak B; Pasalić I; Hrvacić B; Situm K; Kramarić MD; Glojnarić I; Eraković Haber V
Int J Antimicrob Agents; 2008 Aug; 32(2):195-6. PubMed ID: 18571382
[No Abstract] [Full Text] [Related]
19. Protective effects of reconstituted high-density lipoprotein in rabbit gram-negative bacteremia models.
Hubsch AP; Casas AT; Doran JE
J Lab Clin Med; 1995 Dec; 126(6):548-58. PubMed ID: 7490514
[TBL] [Abstract][Full Text] [Related]
20. Esmolol: immunomodulator in pyelonephritis by Pseudomonas aeruginosa.
Dimopoulos G; Theodorakopoulou M; Armaganidis A; Tzepi IM; Lignos M; Giamarellos-Bourboulis EJ; Tsaganos T
J Surg Res; 2015 Sep; 198(1):175-84. PubMed ID: 26073350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
